A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Genmab
Gilead Sciences
Newave Pharmaceutical Inc
MacroGenics
Acerta Pharma BV
Xencor, Inc.
Astellas Pharma Inc
Novartis
Aziende Chimiche Riunite Angelini Francesco S.p.A
Fore Biotherapeutics
MedImmune LLC
MedImmune LLC
Morphotek
INSYS Therapeutics Inc
MedImmune LLC